TNFRSF9 and neoplasm: The administration of this conjugate after tumor irradiation was used to induce an optimal 4-1BB co-stimulation at the tumor site that in turn enhanced tumor immunity and inhibited tumor growth, while no toxicities classically associated with systemic administration of 4-1BB ligands was observed.